GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Insider Ownership

LumiraDx (LumiraDx) Insider Ownership : 0.00 % (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, LumiraDx's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, LumiraDx's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, LumiraDx's Float Percentage Of Total Shares Outstanding is N/A.


LumiraDx Insider Ownership Historical Data

The historical data trend for LumiraDx's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Insider Ownership Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Insider Ownership
- - - -

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LumiraDx Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.